A Paradigm Shift
Precision Medicine For Alzheimer's Disease Using Patented DNA Nanotechnology
Drugs are prescribed based on patient history, toxicology and on a trial and error basis. Esya's platform enables quantitative measurement of individual response to drugs for personalised medicine.
A paradigm shift in understanding how Alzheimer's disease manifests opens up a whole new way of diagnosing, treating and managing the disease.
What We Do
Diagnose Before Symptoms Manifest
Patented intracellular analytics using DNA nanoprobes, combined with AI, applied to neurodegenerative disease before symptoms appear.
Measuring Disease Progression
Track Progression Over Time
Quantitative readouts taken at intervals, so change within the same patient can be measured rather than inferred.
Organelle-Targeted
Unique Organelle-Targeted Assays
Our probes report from inside the endosome, the lysosome and the trans-Golgi network, where the earliest changes occur.